Clinical Study
Immune Response following Liver Transplantation Compared to Kidney Transplantation: Usefulness of Monitoring Peripheral Blood CD4+ Adenosine Triphosphate Activity and Cytochrome P450 3A5 Genotype Assay
Table 1
Backgrounds of LDLT patients.
| | LT-L group () | LT-H group () | value | | IMK < 225 |
| | Average age | 43.6 (3–65) | 41.7 (1–68) | NS | | Male/female | 16/7 | 32/15 | NS | | MELD score | 14.1 (9–32) | 16.0 (8–35) | NS | | Etiology of LDLT | | | | | HCV (HCC) | 8 (5) | 15 (8) | NS | | HBV (HCC) | 2 (0) | 4 (2) | | | PBC | 3 | 10 | | | BA | 1 | 6 | | | Alcohol | 4 (2) | 4 | | | Others | 5 | 8 | | | CMV serology test | | | | | R-seropositive | 5 (21.7%) | 12 (25.5%) | NS | | D-positive/R-negative | 8 (37.8%) | 15 (31.9%) | | | D-negative/R-negative | 10 (43.5%) | 20 (42.5%) | | | R-CYP3A5 | | | | | *1*1 or *1*3 | 7 (53.8%) | 6 (20.7%) | 0.032 | | *3*3 | 6 | 23 | | | D-CYP3A5 | | | | | *1*1 or *1*3 | 6 (46.2%) | 13 (44.8%) | NS | | *3*3 | 7 | 16 | | | Median months after LDLT | 39.2 (1.4–71.4) | 43.1 (1.8–67.5) | NS |
|
|
IMK: ImmuKnow, MELD: model for endstage liver disease, LDLT: living donor liver transplantation, HCV: hepatitis C, HCC: hepatocellular carcinoma, HBV: hepatitis B, PBC: primary biliary cirrhosis, BA: biliary atresia, CYP3A5: cytochrome P450 3A5, CMV: cytomegalovirus, R-: recipient, and D-: donor.
|
